Myocardial viability itself influences chronic coronary patency after coronary angioplasty  by Kano, H. et al.
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PTCA Outcomes In High Risk Patient 
Subsets 
Wednesday, April 1, 1998, 9:00 a,m,-11:00 a,m, 
Georgia World Congress Center, West Exhibit Hall Level 
Presentation Hour: 9:00 a,m,-10:00 a,m, 
~ Clinical Outcomes of PTCA In Patients With Renal 
Failure: A Matched Control Study for Comorbld 
Factors 
R,W, Aslngor, T,D, Henry, C,A, Hersog, R,L, Kano, Hennaptn Cnunly 
Mt~ltcal Canl~r ~nd the Unlv~rMy of Mlnn~lof~, Minneapolis, MN, USA 
RIIlultl of PTCA in pin with tonal disease on hamodiatysla hays h,}on dlsap. 
pointing with variable primary success, high pnceduni oomplloation rotes, 
and poor long term outcomoo, Mnnt reports have boon tam small acres 
not oontnlled for oomofold racism, We nvlswed our PTCA oxparonce In 
?'/pts with meal dlsoaao (RD) over a 5S month pared; 13 with ¢matlnlna 
;.2,0 but not on dialysis, 49 dialysis dependant, and 15 post nnal transplant 
not on dialysis, Ea¢:h RD pt was matched with a PTCA 'genial' ((]natlnine 
~P-0) over the same period tot age, gander, diabetes ~nd parlous conns~/ 
nvasaulaflletion pfooeduna, 
Despite matching for those features, RO pts had higher r~tes 0t other 
vaaoular disease (peMpher~l, aedta, or ~nbral), 50% ve 2~%, p - 0,00t, 
hypof~nsion 9g% ve "/8%, p ,. 0,001, and loft main disease, 9% vs 3%, p 
,~ O,Og trian 'cJontnls," PTCA lesion types warn more cemptes for RD than 
"confetti': 5% vs 16% TyCO A, 1P.% va 20% Type I~I, 44% ve 41% 'I'~ypo B~, 
39% vs 1S% Type C (p .. 0,00t), 
The pflmaW su~ess rate for PTCA In RD pt~ and 'controls' was 89% 
and 9"/% (p ¢ 0,05) end for procedural MI 3% and 4% (p = NS). Then 
wen no pncedum slated strokes or deaths, Koplan.Melor survival analysis 
48 months following PTCA showed a lower eardiac event (redo PTCA, MI, 
CASe, sad death) fma survival for those with RD ve "controls', 53% vs 
7(1%, p ..~ 0,00~, There wee no dlfk~nnce in the incidence of cardiac events 
between the 3 st, ibgroups el RD pts, Our nautts indicate acceptable primaq/ 
success al~l complication rates for PTCA in RD pts but confirm poor long 
term outooll~a nd extend the observation of poor long.term outCOmes to 
R0 pts not on dialysis even If they were a/p renal transplant 
~ Small Coronary  Vaaasle: A Target for Suitable 
Parcutaneous Ravaa©ularlzatlon In the New 
Device Era? 
H, Schunkert. L, Hermit, IF, Patactos Massachusetts General Hospital, 
Harvard MedCaf School. BosUn, MA, USA 
Improvements in device technology h~s resulted in an increased success rate 
and a decreased complication rate in pts undergoing pomutaneous raves. 
cularizstton, However, small vessels have been largely excluded from major 
shift in device technology Thus, we compared the results of porcutaneous 
revasculsrtzation in 81g pts with vessels .:2,5 mm with those of 1,493 pts 
with vessels >25 mm Pts with small vs~ssls were older (65 ~: 12 vs, 63 
12 yea~) and presented more frequently with female gender (39 vs, 30%), 
diabetes (27 vs, 18%), CHF (9 vs. 6%), vascular disease (15 vs. 11%) and 
multivesssl disease (59 vs. 4g%), (p < 0,01, each). In addition, AHAJACC 
type C lesions was found morn frequently In small vessels (10 vs. 6%), In 
contrast o sthnts (18 vs, 43%), conventional balloon PTCA (73 vs. 50%) and 
rotablsticn (16 vs, 8%) were used more often in smaller than larger vessels (p 
.0.0001, each), In pts with small vessels, success rates were lower (92 vs. 
96%, p = 0.0006) and major adverse events (death, Q-wave MI, emergency 
CABG) occurred more frequently (3.4 vs 2%, p = 0,04). Multivariate analysis 
identified sm~ll vessel as independent predictor el combined maior events 
(odds rails 2.2, p < 0.005). 
Cotctusions: 1) In the current device era, pts with small vessels carry 
higher risks and have slightly lower chances for successful revasculariza- 
lion, 2) In contrast o previous PTCA registries, the new device era generates 
reference vessel diameter as an important morphological predictor of out- 
come, 
~ L a t e  (12 yr) Survival Is Not Better in Diabetic 
PPtlents Undergoing Coronary Bypass Surgury 
Compared With Balloon Angloplasty 
D A. Hatch, A. Merdler, M Ftugelmsn, H.$, Rennert, G. Merin, G. Uretzky, 
J. Shahla, B.S, Lewis. Lady Davis Carmel Medical Center and Technion liT, 
Haifa, Israel 
Background; Pts with coronary disease and diabetes mellitus (DM) treated 
by balloon angioplasty (PTCA) were reporled to have poorer 5 yr outcome 
than those teated by bypass surgery (CABG). We examined single center 
12 yr survival In pt cohorts with multlvessal disease with and without DM 
teated by PTCA or CABG In 1984-8. 
Methods: 95 consecutive pta had _>1 vessel PTCA end 177 similar pl l  
CABG, referred by physicians not performing PTCA at that time. Age, prior 
MI, hypertension and pnvalence l OM wen similar In CASe ve PTCA (NS), 
Men CASe pie had 3 yeast' dt0cuo (60.5% ve 37,9%, p < 0.001 ). In 53% of 
CABG, an Internal mammary atlery was used, Analysis ~ed Keplnn.Meter 
curves end the Iog.nnk test, 
a,8 
0,6 ,so 
a4 t " .  P:rcA l f oM~ No OM 
i P xo,oonl 
t ;~ ,~ 4 s a t s s to t~ 
Yeaf~ 
Con~cta~; 1,11~ yr survival alter nvaanulat~atlon was decreased in 
diabetics, ~, Su~vat was not better in pie undeqlotng CABG ve PTCA 
11t e4,t 0t i o@t,,rmlna.t, ot , .  
I~tkmtl With 6mail Vmmel O lmu who 
UndenNnt Coronary Angloplaaty; Impllaatlon of 
Abnormal Gtueoee Toleranae 
Y, OMauka, S, Mlyalaki, A, Ithh. S, Oaikoku, L Mont. 1', Matsumote, Y. Gels. 
H. Nonogt, Nalk:~nat Ca~scutar  Co.let, Su~a, Ja, ean 
Background: Pabents (pts) wlth diabetes mellltus (DM) and impaired glucose 
tolenrce (IGT) lmquootly show severn com~aW d~ease ¢ h a ~  by 
diffuse and small vessels in angtography, and am known to have untavocable 
pmgnoala. To determine the ¢am~a¢ event of small vessel disease 
abnormal glucose tolennee (AGT) 559 pts (69 pie with DM, 120 pts with 
IGI~. 1~(,, 2,~'~, respectively who underwent first successful elective balloon 
eaglopleaty (BA) were analyzed. 
Methods: Pte were divided into 4 groups acco~Im9 to mtem~¢e vesset 
diameter (RF) baron BA: 167 pts with norreal glucose tolerance (NGT) and 
RF <2.5 mm (Group SN), 203 pts with NGT and ftF _>2.5 mm (Group LN), 
97 pts with AGT and RF <2.5 mm (Group SO), and 92 pts with ACT and 
RF _>2.5 mm (Group LD), The cardiac event (repeat corona W angiol:¢asty, 
corona W bypass surge W, acute myoca~ltal intamtton and death) for 8 yea:'s 
alter BA were compared among 4 groups 
Results: There were no difference in patient's demographics. Despite 
similar MLD alter BA in Group SN and SO, Group SD showed unfavorable 
prognosis (Figure). 
1'? I ~ ' ~  . . . . . .  " ' ' "  ( ; I f~Ue 1"  
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Conclusions: An important determinant for long-term p,'ognosis is a pres- 
ence of ACT, per, so, and is not small vessel diameter. 
111 64-1 02 1 Myocardial Viabil ity Itself Inf luences Chronic 
Coronary Potency After  Coronary Angloplasty 
H. Kano, K. Aonuma, H. Hachiya, J.-c. Oh, I. Kobayashi, Y. Yamauchi, 
A. Koike, M Hime. Yokosuka Kyosai General Hospital, Kanagawa. Japan 
We hypothesized that the chronic potency of culplit lesions after coronary 
angioplasty (P-CA) could be affected by myocardial viability of the target 
region. To assess the influences o! myocardial viability on post-PTCA resteo 
nests, a total of 50 patients (pts) with healed myocardial infarction and angina 
undeP, vont resting state Thallium ~°l (1"1) scintigrephy just prior to PTCA, and 
follow-up coronary angiography 6 months after PTCA. Pts who needed intre- 
coronary stenting were .~xn~ur.'ad. From the results of myocardial TI uptake, 
pts were divided into 2 groups~ Group 1 consisted of 25 pts (29 lesions) with 
fixed TI defect; and Group 2 consisted of 25 lots (28 lesions) with normal TI 
uptake. In pts with normal TI uptake, PTCA reduced restenosis compared to 
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PTCA in I~  ~ fixed 1"1 defect, Details were as fOllOWS; 
Grou~ 1 Gfou~ ~ P v~ 
R e ~  (ram) ~83t  043 21~ t 0~5 NS 
MLD P~ (ram) 046 t 0.44 0 .'~ • 0 35 NS 
MLD Po~ (mini 2,32 t 048 2 .23 ,0  57 NS 
MOL F/IJ ( ram) 158±0.53 210 ,073 '  ~005 
%0~ P~ 630 z 16 2 80,4 * '110 NS 
~P0M 182 ~ 10.4 ~1 t 10.~ N~ 
~ppeam to w=~¢l~ ~ ch,~,,-,,~ c~naw pate~¢y attef PTCA 
Impm~ld I~ t lolplt l l  Oulmome lot ~ W~h 
~ Left ~ r  Oy~un~km who 
u~k.~w A~k,pm~ 
Pa!~m= ~ a Jow ~ ~ract~ 1~25%) who u~cle~o comMw argo- 
I~t~ am ~ ~ ~ We ~ Be h ,~ J~m mat me re~,~me~ 
m the le,~m~gy and the ~ of ~,-,m ~ m~m~e me ot~come 
m theee parlays+ ~ w e ~  t20 pa~ents ~ a fow ~ lractmn 
who ~ omor',a~ a* - - ,~  ¢1~ l~Bl-t~14 (Group I) to 47 pa- 
(Group II)_ The perce~ ol.."ah*m~ unnt iow qectmn hacto~ who ~ 
a~gmldaS~ mmmhve to llPze tolal p',,p. .  _~,,~.~ for lhe same Im~e period wa~ 
hlghor m group II (1+2% vts 0.6%, p < 0.0001). ~ d~ra¢lzm~i~ were 
ezgcept 11ol ~,1 ~ po~,~,_f--~ m grOUp It (65 v/S 61 years, p = 0 .~)  r 
Ao~lecfosureo¢¢tmed momhequem~ mgfoupl(17.5% vtS2.1%, p ~ 0.01). 
Slents m used more heq~ m gloup II (23+4% v/s 42%. 0 = 0+0(~4). 
The use o~ in l~ao~c h .~nn pump was sa~ax ~ be~ gn~p~ 12-5% v/s 
21. p = ns). In ~ co~ona~ ar~ bypa~z stege~/a~l daslh was morn 
commo~ m group I (10.~% v+ 0%, p : O02). One year e~,~nl Iree sunm,.al 
was 56% in g~up I and 54% m greup Ii (p = 02). 
Conc~/on- More pa in ts  ~ severe lelt veofncu~ have 
been aemmpeed wdh ~ m rece~ years. Tha hosp~ ou~-ome is 
moeasm~y more ~ .  Loc~:J lemt o~',.~,-~e needs to be e.v-a k.~a~L,d o~e.r 
a Io~ge~ pe~d ol ~m~e. 
Ooes P e ~ J  MI I ~  PTCA Reduce  
Clinical Restenos is?  
CP~ Nannso D. Mdla~, R.M Ca~. E J .  Topoi. TtJe ~ C-~ 
Founda~o~ Ck~md OH. USA 
Adpmct~ treatment ol PTCA w~h ar.,,:.,.~,T, ab ~s a. ,~x~t~l w~th 
reductmns m early ,.,~w~ts. but the effects of p~atelat GP Ig~lla receplm" 
antagon~ Iberapy on ~mcal res len~s,  as detirmd by lato ta+,get vessel 
mvasculanzation (TVR), remains uncorlam as conflfcZmg ~ hame 
I~=e~ reached in recent n~dlJ~efstor t iala+ We souQt~t to ~ W4,XEH~Ier 
the striking re~ucti~t m perq~0cedural MI afforded by ab~L, mT~tb ~ con- 
found an accumle assessment ol the drug's effects on the need for lato TVR 
In the I~lCebO-CO~tro~ed EPIC toal. 2.099 patients wilh high-rrsk ~ or 
an~0graph¢ features underwent PTCA or alberecfomy and were ~,+o~:,¢-,:.- 
~.ely followed for 3 yearn. Within ~ study pol~dalm¢~. I ~  CK 
e levat~ was a sKj.ificant predictor of late modalily. Among patients w~n 
elevated CK, however, a paradoxical decrease in the need for late TVR 
was present. This relationship became ~ l y  mere profound as the 
megn i~ of CK release increased+ 
CK raho 3 y~ m:.rtalffy (%) 3 ~ ~ % (Rtsk Rabo. 9'5%CI) 
Normal 64 29 8 - 
1, nom~l 6.2 27.9 (0+92. O.-5-1.14) 
:2 • 6.4 25.4 (0.79. 060-1 03) 
~3, 76 24 8 (0.75. 0.55-1 01) 
"5~ 9 1 20.8 (062. O 42-092) 
"" lOx 10 4 16 .9  (051.0.29-O.91) 
Is ~ r  Int~xttMIon m ~ I ,b An, ly, ls 
Morn A~:unm m Immm~mml tn-mmmm A m  
l : v ln t l  A t i l t  P f lml ry  PT~A?  
R l~Phenmm, L  Genes, W,W+ O'NWlt, 14~am i[kmm~om ~ 
Oak, 4~ch~g+m. USA 
>+ ~ ~,+~ ~,~:~d~ ~ m ~ ~ .  O ~  ~ ~ ~ 
in+hol4t~al ~ MI, or a~hem~ Pnma~ FrC.,A was I~ffomted m 9116 
pa l~,  of whom 1.9",. had mMI and 10Ji% had ~ ~ e~ly ee~ 
la~ o~ ~ o~ mMI was m~l  mt~a~s ~30% or ~ we#eece ota 
TIMI Ik.w+ am+ ~',,T.-,--4X+S 7~te  were not pmdtct~m, 
Rec~em Mt P ra te  CI' P vaJue Cf 
SIm*'mms 00015 0¢~0 00007 P. ,~,~ 
Demecl~m~ 0 (X]O? O.~l NS 
0004 0~,~, 0CO~ 
O0t 025 NS 
016 
" ~  comaCn~ ~'4~ez iSomenr,' D) = be~e~ pe~l¢l~ al~rdy 
T~'efo~. opma~ m~eq~aaon appea~ to be supe~ fo corn ~a 
ana~y~ m pred¢-mg .~ho~d nacunent acbe~a or .m~fameon. Whee~ 
mm is clue to use ol gonmscopc findings ~ch  were nm mcomed on cme, 
acu~ usa of d,g*la~ m~0m~ or gmat~ ~r ' ,~r  e.,¢meeece desemam fu~her 
11164-106J I n - V i ~ ~ m l d ~ e f  
~aJury Us~Z Va~u~ 
Aeeuslf¢ Em;,~;,;,-,~ 
A- I~ .  ¢~1, J.M FC~las, CJ. Da~dso~ LF. Mocllm:~ D.D. McPhem~ 
Oe~maeem o~ Me,~,~ Noe~e~m Unn4a~y Medca~ Sc~o~ ~ 
mmo~ uSA 
Backgrmm~ We have immm~my dem,.,m+,,,~ed m-vain that mhefmckmmc 
(ATI-q aJrtsnal trireme +,,~, sour¢l as it expanencas meclwnmal dmmlmon. 
Me~floo~: TO fodl~r cbaraclenze acoustic + v ~  (AE) pmllems and 
to ~;y  tf AlE occur m-v~vo at the ~e of begoon a n ~  (BA), 24 
human atonal speomens oblamed post-mort~ and 8 ATH asd conlrel at. 
tenes m~wNo (n~zJswme) were evaluated Artones were ~ lo BA wflh 
s,~naneous moo ing  o( AlE usn~ a ~ i~=eele¢l~ ~a,~- 
dm+-e+. The recorded +~,-,~Is were m-~ized m IM Imme domain using we.,mCet 
teG-.-,Cmes and m lhe frequency domain using Fourier t,~+%-,~p+as, and
chamctmzzed a,~:,+~G.-~j m tbe t~e of ,~_ _,c~J trauma using K,+,~.+,-.+,+ neural 
rmtwork ~ 
P.est.dls: Vascular AIE were demormtraled to occur be;-,~,m~,-+ 30 and 5000 
Hz+ Umng q~m:trograms wilh Koh+.-,~ dasmfmaZton, lhe sounds were char- 
aclenzed as no~eeless, plaque Iraclzae aml lasrlng. The io-vwo dala i+~¢afe 
fewer ex1~-,~us r:,~,~-,as nd 1ha same AE ~ as ,~-~-,~d in ff~e + 
v~ro s~dms. Tean.g m ~ w~ rela1~ely Ion9 (0.4-1,0S) ~;~r+'  
AE. pagoo~ opor,ng with shoder and lower frequency AE. and frectum wi1~ 
even sha,ler (0.1 s) and "c~per' AE 
Conctus~n: We have demonstrated mat vascular ecous~ emtssk~ 
eccur fogo~ng amemma mjury bom m-vitro and m-~vo. Wavefo~n ar~/m 
helps to ~ r  dL~bngutsh normal from pat t~ vascular iojury. ~ data 
supparl the ~- ,c~ of ush'Kj a¢ous~ em=sions as a meens of mor~ortng 
and optin'nzing balloon anojol~asty 
Mechanistically. while it is unlikely that CK elevation prevents vascular 
renanowing per se. myocardial necrosis impairs the clinical manifestation of 
restenosis, thereby reducing the need for ischemia-driven "l V'R. 
Conclusion: In the EPIC study, patients with pariprocedural MI were less 
likely to develop clinical restenosis as measured by the need for TVR at 3 
years. This novel finding (1) highlights a mechanism for potential discordance 
between anglographic and clinical measures of restenosis, and (2) has im- 
plications for future clinical trials, as therapies which reduce periprocedurat 
MI may be associated wit,1 a perceived excess of restenosis when moasured 
by the need for TVR+ 
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